The relationship between blood IL-12p40 level and melanoma progression

International Journal of Cancer

Volumn 136, Issue 8, 2015, Pages 1874-1880

  Fang, Shenying ^a   Wang, Yuling ^a   Chun, Yun Shin ^b   Liu, Huey ^a   Ross, Merrick I ^a   Gershenwald, Jeffrey E ^a   Cormier, Janice N ^a   Royal, Richard E ^a   Lucci, Anthony ^a   Schacherer, Christopher W ^a   Reveille, John D ^a   Sui, Dawen ^a   Bassett, Roland L ^a   Wang, Li E ^a   Wei, Qingyi ^c   Amos, Christopher I ^d   Lee, Jeffrey E ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Virginia Piper Cancer Institute   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cytokines; Early stage; IL 12p40; Melanoma; Progression

Indexed keywords

INTERLEUKIN 12P40;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN SUBUNIT; SEX DIFFERENCE; TUMOR RECURRENCE; VALIDATION PROCESS; BLOOD; DISEASE COURSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY;

DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-12 SUBUNIT P40; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS;

EID: 84922553255     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29182     Document Type: Article

References (14)

1. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
2. Fallarino F, Uyttenhove C, Boon T, et al. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J Immunol 1996;156:1095-100.
3. Quaglino E, Rovero S, Cavallo F, et al. Immunological prevention of spontaneous tumors: a new prospect? Immunol Lett 2002;80:75-9.
4. Cooper AM, Khader SA. IL-12p40: an inherently agonistic cytokine. Trends Immunol 2007;28:33-8.
5. Abdi K, Singh NJ, Spooner E, et al. Free IL-12p40 Monomer is a polyfunctional adaptor for generating novel IL-12-like heterodimers extracellularly. J Immunol 2014;192:6028-36.
6. Carreno BM, Becker-Hapak M, Huang A, et al. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest 2013;123:0.
7. Langrish CL, McKenzie BS, Wilson NJ, et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004;202:96-105.
8. Langowski JL, Zhang XQ, Wu LL, et al. IL-23 promotes tumour incidence and growth. Nature 2006;442:461-5.
9. Amos CI, Wang LE, Lee JE, et al. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet 2011;20:5012-23.
10. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
11. Nagai H, Oniki S, Fujiwara S, et al. Antimelanoma immunotherapy: clinical and preclinical applications of IL-12 family members. Immunotherapy 2010;2:697-709.
12. Riley JL. Combination checkpoint blockade-taking melanoma immunotherapy to the next level. N Engl J Med 2013;369:187-9.
13. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
14. Whitcomb BW, Perkins NJ, Albert PS, et al. Treatment of batch in the detection, calibration, and quantification of immunoassays in large-scale epidemiologic studies. Epidemiology 2010;21:S44-S50.